ScinoPharm Taiwan, Ltd. (TPE:1789)
18.95
+0.15 (0.80%)
Aug 19, 2026, 1:30 PM CST
ScinoPharm Taiwan Revenue
ScinoPharm Taiwan had revenue of 678.51M TWD in the quarter ending June 30, 2026, a decrease of -9.23%. This brings the company's revenue in the last twelve months to 3.07B, down -3.97% year-over-year. In the year 2025, ScinoPharm Taiwan had annual revenue of 3.16B, down -7.13%.
Revenue (ttm)
3.07B
Revenue Growth
-3.97%
P/S Ratio
4.85
Revenue / Employee
5.68M
Employees
540
Market Cap
14.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.16B | -242.86M | -7.13% |
| Dec 31, 2024 | 3.41B | 220.20M | 6.91% |
| Dec 31, 2023 | 3.19B | -77.96M | -2.39% |
| Dec 31, 2022 | 3.26B | 501.71M | 18.16% |
| Dec 31, 2021 | 2.76B | -320.59M | -10.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grape King Bio | 10.28B |
| YungShin Global Holding | 7.84B |
| Standard Chemical & Pharmaceutical | 7.08B |
| TTY Biopharm Company | 6.65B |
| Synmosa Biopharma | 6.37B |
| Formosa Laboratories | 4.64B |
| Center Laboratories | 1.66B |
| SCI Pharmtech | 1.26B |
ScinoPharm Taiwan News
- 8 months ago - ScinoPharm Wins First FDA Approval With Glatiramer Acetate Injection For Multiple Sclerosis - Nasdaq